Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies (LQDA)
:LQDA
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.4Last Year’s EPS
-0.54Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 19, 2025
|% Change Since: 0.88%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment. While there were significant strategic advancements and promising clinical trial results, financial challenges and a decrease in revenue were also highlighted.Company Guidance
During the 2024 financial results and corporate update call, Liquidia Corporation provided guidance on several key metrics and strategic objectives for 2025. The company anticipates a transformational year, driven by the potential final approval and launch of YUTREPIA for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) after gaining clinical exclusivity on May 23, 2025. Liquidia aims to secure a strong market position by highlighting YUTREPIA's best-in-class inhaled prostacyclin profile, targeting dose levels three times higher than the therapeutic target of nebulized TYVASO. Additionally, they reported promising results from the ASCENT trial, including a mean improvement of 26.4 meters in the six-minute walk test at week eight. Financially, Liquidia expanded its financing agreement with HealthCare Royalty Partners to potentially provide up to $100 million, supporting the planned launch and ongoing developments, with the goal of reaching profitability without additional capital needs. During 2024, the company reported $14 million in revenue, a decrease from the previous year, and a net loss of $130.4 million. Research and development expenses increased to $47.8 million, driven by investments in the L606 program and YUTREPIA research. General and administrative expenses also rose significantly to $81.6 million, reflecting personnel and legal costs associated with YUTREPIA-related litigation.Strategic Imperatives for Growth
Liquidia is focusing on four strategic imperatives including the launch of YUTREPIA for PAH and PH-ILD, advancing its clinical profile, capturing market share, and advancing treatment options with L606.
Positive ASCENT Trial Results
The ASCENT trial demonstrated an improvement in the six-minute walk test by 26.4 meters at week eight, surpassing the 16 meters at week eight observed in the TYVASO Phase III trial.
Strong Partnership with HealthCare Royalty Partners
Liquidia expanded its financing agreement with HealthCare Royalty Partners, securing up to $100 million in additional financing.
---
LQDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LQDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 19, 2025 | $14.74 | $14.92 | +1.22% |
| Nov 13, 2024 | $10.63 | $10.27 | -3.39% |
| Aug 07, 2024 | $11.06 | $10.68 | -3.44% |
| May 13, 2024 | $12.14 | $11.96 | -1.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Liquidia Technologies (LQDA) report earnings?
Liquidia Technologies (LQDA) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Liquidia Technologies (LQDA) earnings time?
Liquidia Technologies (LQDA) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LQDA EPS forecast?
LQDA EPS forecast for the fiscal quarter 2025 (Q1) is -0.4.
---